| Assessment Status | Rapid Review Complete |
| HTA ID | 23043 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 21/07/2023 |
| Rapid review completed | 24/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.